OBJECTIVES: We investigated the effects of a novel ultrapotent poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, PJ34, on cardiac and endothelial dysfunction in a rat model of chronic heart failure (CHF). BACKGROUND: Overactivation of the nuclear enzyme PARP importantly contributes to the development of cell dysfunction and tissue injury in various pathophysiologic conditions associated with oxidative stress, including myocardial reperfusion injury, heart transplantation, stroke, shock, and diabetes. METHODS: Chronic heart failure was induced in Wistar rats by chronic ligation of the left anterior descending coronary artery. Left ventricular (LV) function and ex vivo vascular contractility and relaxation were measured 10 weeks after the surgery. Nitrotyrosine (NT) formation and PARP activation were detected by immunohistochemistry. RESULTS: Chronic heart failure induced increased NT formation and PARP activation in the myocardium and intramural vasculature, depressed LV performance, and impaired vascular relaxation of aortic rings. PJ34 significantly decreased myocardial PARP activation but not NT formation, and improved both cardiac dysfunction and vascular relaxation. CONCLUSIONS: Poly(ADP-ribose) polymerase inhibition represents a novel approach for the experimental treatment of CHF.
OBJECTIVES: We investigated the effects of a novel ultrapotent poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, PJ34, on cardiac and endothelial dysfunction in a rat model of chronic heart failure (CHF). BACKGROUND: Overactivation of the nuclear enzyme PARP importantly contributes to the development of cell dysfunction and tissue injury in various pathophysiologic conditions associated with oxidative stress, including myocardial reperfusion injury, heart transplantation, stroke, shock, and diabetes. METHODS:Chronic heart failure was induced in Wistar rats by chronic ligation of the left anterior descending coronary artery. Left ventricular (LV) function and ex vivo vascular contractility and relaxation were measured 10 weeks after the surgery. Nitrotyrosine (NT) formation and PARP activation were detected by immunohistochemistry. RESULTS:Chronic heart failure induced increased NT formation and PARP activation in the myocardium and intramural vasculature, depressed LV performance, and impaired vascular relaxation of aortic rings. PJ34 significantly decreased myocardial PARP activation but not NT formation, and improved both cardiac dysfunction and vascular relaxation. CONCLUSIONS:Poly(ADP-ribose) polymerase inhibition represents a novel approach for the experimental treatment of CHF.
Authors: Sándor Bátkai; Pál Pacher; Zoltán Járai; Jens A Wagner; George Kunos Journal: Am J Physiol Heart Circ Physiol Date: 2004-04-01 Impact factor: 4.733
Authors: Orsolya Szenczi; Péter Kemecsei; Max F J Holthuijsen; Natal A W van Riel; Ger J van der Vusse; Pál Pacher; Csaba Szabó; Márk Kollai; László Ligeti; Tamás Ivanics Journal: Biochem Pharmacol Date: 2005-01-12 Impact factor: 5.858
Authors: Sandra Levrand; Christine Vannay-Bouchiche; Benoît Pesse; Pal Pacher; François Feihl; Bernard Waeber; Lucas Liaudet Journal: Free Radic Biol Med Date: 2006-06-07 Impact factor: 7.376
Authors: Dirk M Maybauer; Marc O Maybauer; Csaba Szabó; Martin Westphal; Lillian D Traber; Perenlei Enkhbaatar; Kanneganti G K Murthy; Yoshimitsu Nakano; Andrew L Salzman; David N Herndon; Daniel L Traber Journal: Biochem Biophys Res Commun Date: 2008-10-23 Impact factor: 3.575